U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicabl)
TEB	AA	2002/0049255A1	4/25/02	Gamache, et al.			08/13/01
TEB	AB	2003/0018044A1	1/23/03	Peyman			9/19/02
TEB	AC	4,997,652	3/5/91	Wong			
TEB	AD	4,853,224	8/1/89	Wong			
TEB	AE	5,164,188	11/17/92	Wong			
TEB	AF	5,443,505	8/22/95	Wong, et al.			
TEB	AG	5,476,511	12/19/95	Gwon, et al.			
TEB	AH	5,632,984	5/27/97	Wong, et al.			
TEB	AI	5,766,242	6/16/98	Wong, et al.			
TEB	AJ	5,780,647	7/14/98	Vuligonda et al.			
TEB	AK	5,824,072	10/20/98	Wong			
TEB	AL	6,060,463	5/9/00	Freeman			
TEB	AM	6,378,526 B1	4/30/02	Bowman, et al.			
TEB	AN	6,397,849	6/4/02	Bowman, et al.			
TEB	AO	6,416,777 B1	7/9/02	Yaacobi			
TEB	AP	6,489,335 B2	12/3/02	Peyman			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
TEB	BA	WO 91/19482	12/26/91	PCT			
TEB	BB	WO 93/06856	4/15/93	PCT			
TEB	BC	WO 95/26734	10/12/95	PCT			
TEB	BD	WO 00/07565	2/17/00	PCT			
TEB	BE	WO 02/41910 A2	5/30/02	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

TEB	CA	Alminger, T.B., et al., (Pyridinylmethyl)*Chemical Abstracts*, Vol. 110, 1989, pg. 692, 57664
TEB	CB	Baker, L., et al., Abstract Pars Plana Jet Injection of Ganciclovir, *IOVS*, 1990;31(4):306
TEB	CC	Ball, S., Concentration change and activity of fluorouracil in the external segment of the eye after subconjunctival injection, *Arch Ophthalmol*, Vol. 107, September 1989, pgs 1276-1277
TEB	CD	Bundgaard, H., Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities, *Design of Prodrugs (Bundgaard, H., ed.) 1985 Elsevier Science Publishers B.V.*, Biomedical Division, Chp. 1, pg. 1-92.

EXAMINER TEB DATE CONSIDERED 6/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	**SERIAL NO.:** 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	**TITLE:** DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	**GROUP:**

	CE	Bundgaard, H., et al., Prodrugs as drug delivery systems XIX. Bioreversible derivatization of aromatic amines by formation of N-mannich bases with succinimide, *International Journal of Pharmaceutics*, 8(1981) 183-192
	CF	Bundgaard, H., et al., Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents, *Int. J. Pharm. 1981 9(1), 7-16*
	CG	Bundgaard, H., et al., Phenyl carbamates of amino acids as prodrugs forms for protecting phenols against first-pass metabolism, *Int. J. Pharm.* 81 (1992) 253-261
	CH	Bundgaard, H., et al., Pro drugs as drug delivery systems. X.imides, urea derivatives, amines and other NH-acidic compounds. *Arch Pharm Chemi, Sci. Ed.*, 1980 8(2) 29-52
	CI	Bundgaard, et al., A novel solution-stable, water-soluble prodrug type for drugs containing a hydroxyl or an NH-acidic group, *J. of Medicinal Chemistry*, Vo. 32, No. 12, Dec. 1989, pg. 2503-2507
	CJ	Bundgaard, H., et al., Prodrugs as drug delivery systems. 43. O-acyloxymethyl salicylamide N-mannich bases as double prodrug forms for amines, *Int. J. of Pharm.*, 29 (1986) 19-28
	CK	Bundgaard, H., et al., Hydrolysis of N-(α-hydroxyalkyl) amide derivatives: implications for the design of N-acyloxyalkyl-type prodrugs, *Intl. Journal of Pharm* 22, (1984) 45-56
	CL	Buur, A, et al., Acta Pharm Nord, 1991 3(1) 51-6
	CM	~~Cheng, Y., et al., Relationship between the inhibition constant (K_I) and the concentration of inhibitor which causes 50 per center inhibition (I_{50}) of an enzymatic reaction, *Biochimical Pharm.*, Vol 22, pp. 3099-3108~~
	CN	Chiang, C., et al., In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres, *J. of Ocular Pharm and Therapeutics*, Vol. 17, No. 6, 2001; pgs. 545-553
	CO	Joshi, A., Microparticles for Ophthalmic Drug Delivery, *Journal of Ocular Pharmacology*, Vol. 10, No. 1, 1994, pp. 29-45
	CP	Einmahl, S. ("A Novel Route of Ocular Drug Delivery: Suprachoroidal Injections Of A Sustained-Release System", Proceed. Int'l. Symp. Rel. Bioact. Mater., 28, (2001), pp. 293-294
	CQ	Einmahl, S., et al., Abstract, Evaluation of a new biomaterial injected in the suprachoroidal space of the rabbit eye, *IOVS*, 2001;42(4) 1 pg
	CR	Giordano, G.G., et al., Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR, *Investigative Ophthalmology & Visual Science*, Aug 1993;34(9), pgs 2743-2751.
	CS	Hansen, K.T., et al., Carbamate ester prodrugs of dopaminergic compounds: synthesis, stability and bioconversion, *J. Pharm Sc.* 1991, 80(8) 793-798
	CT	Herrero-Vanrell, R., et al., Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles and sterilization process, *Pharmaceutical Research*, Vol. 17, No. 10, 2000, pgs. 1323-1328
	CU	Jensen, E., et al., N-substituted (aminomethyl) benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs., *Acta Pharm Nord.*, 1992 4(1) 35042

EXAMINER _____ DATE CONSIDERED 6/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	**SERIAL NO.: 10/617,468**
APPLICANT: P. M. HUGHES, ET AL.	**TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG**
FILING DATE: JULY 10, 2003	**GROUP:**

TEB	CV	Joshi, A., Microparticulates for ophthalmic drug delivery, *J. of Ocular Pharmacology*, Vol. 10, No. 1, 1994
TEB	CW	Kawase, K., et al ., Mitomycin concentration in rabbit and human ocular tissues after topical administration, *Ophthalmology*, Vol. 99, No. 2, February 1992, pgs. 203-207
TEB	CX	Kondo, et al., Concentration change of fluorouracil in the external segment of the eye after subconjunctival injection, *Arch Ophthalmol 1988;106:1718-1721*
TEB	CY	Maritera, T., et al., Microspheres of biodegradable polymers as a drug delivery system in the vitreous, *Invest Ophthalmol Vis Sci* , 32:1785-1790, 1991
TEB	CZ	Nagy, B., et al., Study on subconjunctival application of capsulated tobramycin, *Ann. Immunol. hung*, 25:355-363; 1985
TEB	CAA	Pinilla, I., et al., Subconjunctival injection of low doses of mitomycin C: effects on fibroblast proliferation, *Ophthalmologica*, 1998;212:306-309
TEB	CBB	Thomsen, K.F., et al., Evaluation of phenyl carbamates of ethyl diamines as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism, *Int. J. Pharm.* 1994, 112(2) 143-52

EXAMINER TEB DATE CONSIDERED 6/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

Sheet 1 of 1

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17549 (AP)	SERIAL NO.: 10/617,468
APPLICANT: P. M. HUGHES, ET AL.	TITLE: DELIVERY OF AN ACTIVE DRUG TO THE POSTERIOR PART OF THE EYE VIA SUBCONJUNCTIVAL OR PERIOCULAR DELIVERY OF A PRODRUG
FILING DATE: JULY 10, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
TSB	AA	5,384,333	01/24/1995	DAVIS et al.	514	772.3	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
TSB	BA	WO 96/38133	12/05/1996	PCT	A61K	9/14	Y
TSB	BB	WO 00/03660	07/16/1999	PCT	A61K	2/02	Y
TSB	BC	WO 02/087586	04/26/2002	PCT	A61K	31/513	Y
TSB	BD						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

TSB	CA	Khoobehi, Bahram, et al., *Clearance of Fluorescein Incorporated Into Microspheres From the Cornea and Aqueous After Subconjunctival Injection*, Ophthalmic Surgery, December 1990, Vol. 21, No. 12, pp. 840-844
TSB	CB	Kompella, Uday, et al., *Subconjunctival Nano- and Microparticles Sustain Retinal Delivery of Budesonide, a Corticosteroid Capabale of Inhibiting VEGF Expression*, IOVS, March 2003, Vol. 44, No. 3, pp. 1192-1200
TSB	CC	Lallemand, F., et al., Cyclosporine A delivery to the eye: A pharmaceutical challenge, Eur. J. Pharm & Biopharm, 56 (2003), pp. 307-318
TSB	CD	de Rojas-Silva, M.-V., et al., *Efficacy of subconjunctival cyclosporine-containing microspheres on keratoplasty rejection in the rabbit*, Graefe's Arch Clin Exp Ophthalmol (1999) 237, pp. 840-847
TSB	CE	Saishin, Y., et al., Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model, IOVS, November 2003, Vol. 44, No. 11, pp. 4989-4993
	CF	
	CG	
	CH	

EXAMINER TSB DATE CONSIDERED 6/29/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.